Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.

Neumann U, Ufer M, Jacobson LH, Rouzade-Dominguez ML, Huledal G, Kolly C, Lüönd RM, Machauer R, Veenstra SJ, Hurth K, Rueeger H, Tintelnot-Blomley M, Staufenbiel M, Shimshek DR, Perrot L, Frieauff W, Dubost V, Schiller H, Vogg B, Beltz K, Avrameas A, Kretz S, Pezous N, Rondeau JM, Beckmann N, Hartmann A, Vormfelde S, David OJ, Galli B, Ramos R, Graf A, Lopez Lopez C.

EMBO Mol Med. 2018 Sep 17. pii: e9316. doi: 10.15252/emmm.201809316. [Epub ahead of print]

2.

The effect of a novel turbulence-controlled suction system in the prevention of hemolysis and platelet dysfunction in autologous surgery blood.

Budde H, Riggert J, Vormfelde S, Tirilomis T, Friedrich MG.

Perfusion. 2018 Jul 27:267659118790915. doi: 10.1177/0267659118790915. [Epub ahead of print]

PMID:
30052109
3.

Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.

Alsop J, Medin J, Cornelissen C, Vormfelde SV, Ziemssen T.

PLoS One. 2017 May 5;12(5):e0173353. doi: 10.1371/journal.pone.0173353. eCollection 2017.

4.

Combination treatment of fingolimod with antidepressants in relapsing-remitting multiple sclerosis patients with depression: a multicentre, open-label study - REGAIN.

Bayas A, Schuh K, Baier M, Vormfelde SV; REGAIN Study Group.

Ther Adv Neurol Disord. 2016 Sep;9(5):378-88. doi: 10.1177/1756285616651197. Epub 2016 Jun 3.

5.
6.

Confirmed Disability Improvement In Patients With Active Multiple Sclerosis Treated With Fingolimod Versus Brace: A Matched Comparison of Treatments From The Pangaea And Pearl Registry Studies.

Alsop JC, Bergvall N, Cornelissen C, Vormfelde SV, Medin J, Ziemssen T.

Value Health. 2015 Nov;18(7):A750. doi: 10.1016/j.jval.2015.09.2900. Epub 2015 Oct 20. No abstract available.

7.

Impact of mineralocorticoid receptor polymorphisms on urinary electrolyte excretion with and without diuretic drugs.

Dalila N, Brockmöller J, Tzvetkov MV, Schirmer M, Haubrock M, Vormfelde SV.

Pharmacogenomics. 2015 Jan;16(2):115-27. doi: 10.2217/pgs.14.163.

PMID:
25616098
8.

Educating orally anticoagulated patients in drug safety: a cluster-randomized study in general practice.

Vormfelde SV, Abu Abed M, Hua TD, Schneider S, Friede T, Chenot JF.

Dtsch Arztebl Int. 2014 Sep 12;111(37):607-14. doi: 10.3238/arztebl.2014.0607.

9.

Video-assisted patient education to modify behavior: a systematic review.

Abu Abed M, Himmel W, Vormfelde S, Koschack J.

Patient Educ Couns. 2014 Oct;97(1):16-22. doi: 10.1016/j.pec.2014.06.015. Epub 2014 Jul 5. Review.

PMID:
25043785
10.

Safety relevant knowledge of orally anticoagulated patients without self-monitoring: a baseline survey in primary care.

Chenot JF, Hua TD, Abu Abed M, Schneider-Rudt H, Friede T, Schneider S, Vormfelde SV.

BMC Fam Pract. 2014 May 25;15:104. doi: 10.1186/1471-2296-15-104.

11.

Practice nursed-based, individual and video-assisted patient education in oral anticoagulation--protocol of a cluster-randomized controlled trial.

Hua TD, Vormfelde SV, Abu Abed M, Schneider-Rudt H, Sobotta P, Friede T, Chenot JF.

BMC Fam Pract. 2011 Apr 10;12:17. doi: 10.1186/1471-2296-12-17.

12.

The genetics of loop diuretic effects.

Vormfelde SV, Brockmöller J.

Pharmacogenomics J. 2012 Feb;12(1):45-53. doi: 10.1038/tpj.2010.68. Epub 2010 Sep 28.

PMID:
20877298
13.

Amelogenin-based sex identification as a strategy to control the identity of DNA samples in genetic association studies.

Tzvetkov MV, Meineke I, Sehrt D, Vormfelde SV, Brockmöller J.

Pharmacogenomics. 2010 Mar;11(3):449-57. doi: 10.2217/pgs.10.14.

PMID:
20235797
14.

Implementing the cross-disciplinary subject of palliative medicine (Q13) against the backdrop of recent changes of the legal framework using University Medical School Göttingen as an example.

Alt-Epping B, Jung W, Simmenroth-Nayda A, Russo SG, Vormfelde SV, Nauck F.

GMS Z Med Ausbild. 2010;27(5):Doc67. doi: 10.3205/zma000704. Epub 2010 Nov 15.

15.

The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.

Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, Sabolić I, Koepsell H, Brockmöller J.

Clin Pharmacol Ther. 2009 Sep;86(3):299-306. doi: 10.1038/clpt.2009.92. Epub 2009 Jun 17.

PMID:
19536068
16.

Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers.

Vormfelde SV, Brockmöller J, Bauer S, Herchenhein P, Kuon J, Meineke I, Roots I, Kirchheiner J.

Clin Pharmacol Ther. 2009 Jul;86(1):54-61. doi: 10.1038/clpt.2009.40. Epub 2009 Apr 15.

PMID:
19369937
17.

[SOPHO-NET - a research network on psychotherapy for social phobia].

Leichsenring F, Salzer S, Beutel ME, von Consbruch K, Herpertz S, Hiller W, Hoyer J, Hüsing J, Irle E, Joraschky P, Konnopka A, König HH, de Liz T, Nolting B, Pöhlmann K, Ruhleder M, Schauenburg H, Stangier U, Strauss B, Subic-Wrana C, Vormfelde SV, Weniger G, Willutzki U, Wiltink J, Leibing E.

Psychother Psychosom Med Psychol. 2009 Mar-Apr;59(3-4):117-23. doi: 10.1055/s-0029-1202277. Epub 2009 Apr 6. Review. German.

PMID:
19350471
18.

Atrial natriuretic peptide polymorphisms, hydrochlorothiazide and urinary potassium excretion.

Vormfelde SV, Toliat MR, Nürnberg P, Brockmöller J.

Int J Cardiol. 2010 Sep 24;144(1):72-4. doi: 10.1016/j.ijcard.2008.12.028. Epub 2009 Jan 11. No abstract available.

PMID:
19141362
19.

On the value of haplotype-based genotype-phenotype analysis and on data transformation in pharmacogenetics and -genomics.

Vormfelde SV, Brockmöller J.

Nat Rev Genet. 2007 Dec;8(12). doi: 10.1038/nrg1916-c1; author reply doi/10.1038/nrg1916-c2. No abstract available.

PMID:
19066603
20.

Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9.

Sachse-Seeboth C, Pfeil J, Sehrt D, Meineke I, Tzvetkov M, Bruns E, Poser W, Vormfelde SV, Brockmöller J.

Clin Pharmacol Ther. 2009 Mar;85(3):273-6. doi: 10.1038/clpt.2008.213. Epub 2008 Nov 12.

PMID:
19005461
21.

The social phobia psychotherapy research network. The first multicenter randomized controlled trial of psychotherapy for social phobia: rationale, methods and patient characteristics.

Leichsenring F, Hoyer J, Beutel M, Herpertz S, Hiller W, Irle E, Joraschky P, Konig HH, de Liz TM, Nolting B, Pohlmann K, Salzer S, Schauenburg H, Stangier U, Strauss B, Subic-Wrana C, Vormfelde S, Weniger G, Willutzki U, Wiltink J, Leibing E.

Psychother Psychosom. 2009;78(1):35-41. doi: 10.1159/000162299. Epub 2008 Oct 14. Erratum in: Psychother Psychosom. 2009;78(1):41.

22.

Dimensions of personality--relationship between DSM-IV personality disorder symptoms, the five-factor model, and the biosocial model of personality.

Leibing E, Jamrozinski K, Vormfelde SV, Stahl J, Doering S.

J Pers Disord. 2008 Feb;22(1):101-8. doi: 10.1521/pedi.2008.22.1.101.

PMID:
18312125
23.

The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics.

Vormfelde SV, Toliat MR, Schirmer M, Meineke I, Nürnberg P, Brockmöller J.

Clin Pharmacol Ther. 2008 Jun;83(6):815-7. Epub 2007 Nov 14. No abstract available.

PMID:
18043684
24.

Torasemide transport by organic anion transporters contributes to hyperuricemia.

Hagos Y, Bahn A, Vormfelde SV, Brockmöller J, Burckhardt G.

J Am Soc Nephrol. 2007 Dec;18(12):3101-9. Epub 2007 Oct 31. No abstract available.

25.

Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs.

Vormfelde SV, Sehrt D, Toliat MR, Schirmer M, Meineke I, Tzvetkov M, Nürnberg P, Brockmöller J.

Clin Pharmacol Ther. 2007 Sep;82(3):300-9. Epub 2007 Apr 25.

PMID:
17460608
26.

Genetic variation at the CYP2C locus and its association with torsemide biotransformation.

Vormfelde SV, Schirmer M, Toliat MR, Meineke I, Kirchheiner J, Nürnberg P, Brockmöller J.

Pharmacogenomics J. 2007 Jun;7(3):200-11. Epub 2006 Sep 12.

PMID:
16969365
27.

Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters.

Vormfelde SV, Schirmer M, Hagos Y, Toliat MR, Engelhardt S, Meineke I, Burckhardt G, Nürnberg P, Brockmöller J.

Br J Clin Pharmacol. 2006 Sep;62(3):323-35.

28.

Hydrochlorothiazide efficacy and polymorphisms in ACE, ADD1 and GNB3 in healthy, male volunteers.

Vormfelde SV, Sehrt D, Bolte D, Pahl S, Tzvetkov M, Brockmöller J.

Eur J Clin Pharmacol. 2006 Mar;62(3):195-201. Epub 2006 Feb 1.

PMID:
16450155
29.

Anxiety- and novelty seeking-related personality traits and serotonin transporter gene polymorphisms.

Vormfelde SV, Hoell I, Tzvetkov M, Jamrozinski K, Sehrt D, Brockmöller J, Leibing E.

J Psychiatr Res. 2006 Sep;40(6):568-76. Epub 2005 Nov 28. Erratum in: J Psychiatr Res. 2008 Apr;42(5):424.

PMID:
16313923
30.

CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.

Vormfelde SV, Engelhardt S, Zirk A, Meineke I, Tuchen F, Kirchheiner J, Brockmöller J.

Clin Pharmacol Ther. 2004 Dec;76(6):557-66.

PMID:
15592327
31.

Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research.

Vormfelde SV, Burckhardt G, Zirk A, Wojnowski L, Brockmöller J.

Pharmacogenomics. 2003 Nov;4(6):701-34. Review.

PMID:
14596636
32.

The role of active metabolites in dihydrocodeine effects.

Schmidt H, Vormfelde SV, Walchner-Bonjean M, Klinder K, Freudenthaler S, Gleiter CH, Gundert-Remy U, Skopp G, Aderjan R, Fuhr U.

Int J Clin Pharmacol Ther. 2003 Mar;41(3):95-106.

PMID:
12665158
33.

Enoxaparin or fondaparinux for thrombosis prevention after orthopaedic surgery.

Vormfelde SV.

Lancet. 2002 Nov 23;360(9346):1701; author reply 1702. No abstract available.

PMID:
12457831
34.

Affinities of dihydrocodeine and its metabolites to opioid receptors.

Schmidt H, Vormfelde Sv, Klinder K, Gundert-Remy U, Gleiter CH, Skopp G, Aderjan R, Fuhr U.

Pharmacol Toxicol. 2002 Aug;91(2):57-63.

PMID:
12420793
35.

Death attributed to methadone.

Vormfelde SV, Poser W.

Pharmacopsychiatry. 2001 Nov;34(6):217-22. Review.

PMID:
11778141
36.

Pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance.

Vormfelde SV, Mück W, Freudenthaler SM, Heyen P, Schmage N, Kuhlmann J, Müller GA, Gundert-Remy UM, Gleiter CH.

J Clin Pharmacol. 1999 Feb;39(2):147-54.

PMID:
11563406
37.
38.

Hyperforin in extracts of St John's wort (Hypericum perforatum) for depression.

Vormfelde SV, Poser W.

Arch Intern Med. 2000 Sep 11;160(16):2548-9. No abstract available.

PMID:
10979074
39.

Mortality associated with New South Wales methadone programs.

Vormfelde SV, Poser W.

Med J Aust. 1999 Oct 18;171(8):442-3. No abstract available.

PMID:
10590750
40.

Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6?

Vormfelde SV, Bitsch A, Meineke I, Gundert-Remy UM, Gleiter CH.

Eur J Clin Pharmacol. 1997;52(5):387-90.

PMID:
9272409
41.

Comparative bioavailability of two vitamin B1 preparations: benfotiamine and thiamine mononitrate.

Schreeb KH, Freudenthaler S, Vormfelde SV, Gundert-Remy U, Gleiter CH.

Eur J Clin Pharmacol. 1997;52(4):319-20. No abstract available.

PMID:
9248773

Supplemental Content

Loading ...
Support Center